Literature DB >> 34374822

[Reality of care of colorectal cancer in the State of Brandenburg : With special consideration of the number of hospital cases and certification as a colorectal cancer center].

Maik Sahm1, Constanze Schneider, Stephan Gretschel, Rainer Kube, Andreas Becker, Marlis Günther, Andreas Loew, Kristoph Jahnke, Rene Mantke.   

Abstract

Analysis of the quality of care for colorectal cancer is an essential foundation for further development and is based on the comparison of the goals set and the actual quality of care. This publication presents the reality of care in the State of Brandenburg covering the complete spectrum of treating clinics based on the data of the clinical cancer register. This study analyzed the number of resected and examined lymph nodes, the quality of total mesorectal excision (TME), the residual tumor (R0) resection rate and the proportion of adjuvant therapy of colon cancer in Union internationale contre le cancer (UICC) stage III depending on the operation quota of hospitals and the certification as bowel cancer center according to Onkozert. Apart from the R status, the analyses showed no differences in the qualitative operation data from the clinical cancer register depending on the hospital volume.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Adjuvant therapy; Lymph node status; R0 resection rate; Surgery numbers; Total mesorectal excision

Mesh:

Year:  2021        PMID: 34374822     DOI: 10.1007/s00104-021-01468-9

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  2 in total

1.  Mortality and complication management after surgery for colorectal cancer depending on the DKG minimum amounts for hospital volume.

Authors:  Johannes Diers; Philip Baum; Harald Matthes; Christoph-Thomas Germer; Armin Wiegering
Journal:  Eur J Surg Oncol       Date:  2020-09-25       Impact factor: 4.424

Review 2.  [The development process of colon cancer centres].

Authors:  M Sahm; S Wesselmann; R Kube; N Schöffel; M Pross; H Lippert; S Kahl
Journal:  Zentralbl Chir       Date:  2012-10-31       Impact factor: 0.942

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.